ALK and ROS1 Double-Rearranged Lung Squamous Cell Carcinoma Responding to Crizotinib Treatment: A Case Report

Abstract

Echinoderm microtubule associated protein like 4 gene (EML4)–ALK receptor tyrosine kinase gene (ALK) and ROS1 rearrangements have been demonstrated to be driver genes in NSCLCs that can benefit from crizotinib. ALK rearrangement occurs in approximately 5% of all lung adenocarcinomas and 1.3% of lung squamous cell cancer (SqCC), whereas ROS1 rearrangement accounts for 1% to 3% of all lung adenocarcinomas and rarely, has been reported in lung SqCC.1,2